SCHEMBL1745328

SCHEMBL1745328

CC(C)CNc1nc(-c2ccccc2)cs1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.62
RAB9A P51151 7/20 0.62
NPC1 O15118 6/20 0.62
ALDH1A1 P00352 4/20 0.62
STAT1 P42224 1/20 0.62
MEN1 O00255 10/20 0.57
KMT2A Q03164 10/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
GFER P55789 2/20 0.57
STAT3 P40763 1/20 0.54
GAA P10253 4/20 0.54
LMNA P02545 2/20 0.54
ALOX12 P18054 2/20 0.54
KDM4E B2RXH2 2/20 0.54
HTT P42858 1/20 0.54
SENP8 Q96LD8 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
SENP6 Q9GZR1 1/20 0.52
MAOA P21397 3/20 0.51
MAOB P27338 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18678155 0.87 MAPT (0.56) MAPTRAB9ANPC1ALDH1A1STAT1
SCHEMBL1746613 0.86 MAPT (0.66) MAPTRAB9ANPC1ALDH1A1STAT1
SCHEMBL1747419 0.83 MEN1 (0.71) MAPTRAB9ANPC1ALDH1A1STAT1
SCHEMBL19736598 0.83 MAPT (0.55) MAPTRAB9ANPC1ALDH1A1STAT1
SCHEMBL13685464 0.82 RAB9A (0.50) MAPTRAB9ANPC1ALDH1A1STAT1
SCHEMBL1747328 0.81 RAB9A (0.81) MAPTRAB9ANPC1ALDH1A1STAT1
SCHEMBL1745407 0.80 MEN1 (0.60) MAPTRAB9ANPC1ALDH1A1STAT1
SCHEMBL29470100 0.79 RAB9A (0.61) MAPTRAB9ANPC1ALDH1A1STAT1
SCHEMBL21517172 0.79 MAPT (0.61) MAPTRAB9ANPC1ALDH1A1STAT1
SCHEMBL1820346 0.79 ALDH1A1 (0.76) MAPTRAB9ANPC1ALDH1A1STAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR MAPT 4718/4885RAB9A 2029/4885NPC1 1470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.